Immunity (medical)

Alexion Canada Appoints Karen Heim as New General Manager

Retrieved on: 
Tuesday, April 2, 2024
Circulatory system, Neurology, AstraZeneca, GSK plc, Metabolism, Hematology, Cardiology, Patient, DSM-IV codes, Research, Alexion Pharmaceuticals, Bachelor of Science, Acquisition, University, Senior, Metallurgy, Nephrology, Queen's University, Rare disease, Immunity (medical), Alexion, Ophthalmology, Pharmaceutical industry

MISSISSAUGA, ON, April 2, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.

Key Points: 
  • MISSISSAUGA, ON, April 2, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.
  • In this role, Ms. Heim will lead the Canadian affiliate in its unwavering commitment to helping people affected by rare diseases live longer, healthier lives.
  • "Karen's deep healthcare experience and incredible passion make her the perfect fit to lead this mission in Canada and drive it with expertise and ambition."
  • "Taking on this leadership role at Alexion Canada as it continues to grow, with a focus on research and innovation, is incredibly exciting," says Ms. Heim.

Omniose Announces Scientific Collaboration With AstraZeneca to Research Vaccines for Serious Bacterial Diseases

Retrieved on: 
Friday, January 5, 2024
Medical Supplies, Health, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, Vaccine, CSO, Immunization, Immunity (medical), Membrane, Bioconjugation, Synthetic biology, Infection, Conjugation, AstraZeneca

Omniose, a preclinical biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca to research potential vaccines for bacterial pathogens in AstraZeneca’s early Vaccines & Immune Therapies pipeline.

Key Points: 
  • Omniose, a preclinical biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca to research potential vaccines for bacterial pathogens in AstraZeneca’s early Vaccines & Immune Therapies pipeline.
  • Under the terms of the agreement, AstraZeneca will have exclusive rights to Omniose’s proprietary bioconjugation platform for up to three years, which allows for the development of high-quality vaccines against a range of bacterial pathogens, including multidrug-resistant “superbugs” previously intractable by other methods.
  • Conjugate vaccines are an effective form of immunization however, their use is limited due to the complex chemical process of attaching bacterial polysaccharides to engineered carrier proteins.
  • As part of our ambition to provide long-lasting immunity to millions of people, we are excited to enter into this scientific collaboration with Omniose to explore the role of this novel bioconjugate platform in developing vaccines for bacterial pathogens.”

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

Retrieved on: 
Tuesday, December 12, 2023
Cardiology, Biotechnology, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, VLP, Disease, COPD, Acquisition, Heart, AstraZeneca, RSV, Food, Virus-like particle, Security (finance), Incidence, Pneumonia, Human, Risk, US Foods, Protein, Mortality, Vaccination, Fast track (FDA), Patient, Urinary tract infection, Letter, Death, Vaccine, Hepatitis, Infection, Immune Therapy Holdings, University, Virus, Communication, SARS-CoV-2, VWAP, Viral pneumonia, Asthma, Immunity (medical), Schedule, Respiratory syncytial virus, Pharmaceutical industry

Iskra Reic, Executive Vice President, Vaccines & Immune Therapies, AstraZeneca, said: “This virus-like particle vaccine technology has the potential to transform prevention against severe infectious diseases, including RSV and hMPV.

Key Points: 
  • Iskra Reic, Executive Vice President, Vaccines & Immune Therapies, AstraZeneca, said: “This virus-like particle vaccine technology has the potential to transform prevention against severe infectious diseases, including RSV and hMPV.
  • Icosavax’s lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
  • In Icosavax’s Phase II trial, IVX-A12 showed robust immune responses across RSV and hMPV antibodies, reconfirming previous immunogenicity data seen in the smaller Phase I trial.
  • The data are the first to demonstrate hMPV immune response in a Phase II combination vaccine trial.

HDT Bio to Participate in World Vaccine Congress West Coast 2023

Retrieved on: 
Thursday, November 16, 2023
ID, Safety, Research, Entrepreneurship, National Cancer Institute, ACCESS, Vaccine, Infection, Pathology, Therapy, Senior advisor, Temperature, Immunity (medical), RNA, Pharmaceutical industry, Cancer, Immunotherapy

SEATTLE, Nov. 16, 2023 /PRNewswire/ -- HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, today announced its participation at the World Vaccine Congress West Coast 2023 in Santa Clara, California, from November 27 through 30, 2023.

Key Points: 
  • SEATTLE, Nov. 16, 2023 /PRNewswire/ -- HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, today announced its participation at the World Vaccine Congress West Coast 2023 in Santa Clara, California, from November 27 through 30, 2023.
  • HDT Bio's AMPLIFY vaccine platform combines repRNA coding for an antigen target and LION™ formulation technology to provide a versatile solution for a range of pathologies, from infectious diseases to cancer.
  • HDT Bio's AMPLIFY platform is designed to enhance flexibility of manufacturing, improve stability during storage, while increasing cellular immune responses.
  • "The World Vaccine Congress West Coast 2023 has evolved into an impactful and influential platform, seamlessly integrating advancements in cancer and infectious disease research, bringing together innovative minds in the field of vaccines and immunology.

Studying Immune Cell Aging in Space May Lead to New Therapies for Patients on Earth

Retrieved on: 
Tuesday, October 3, 2023
Infection, ISS National Lab, SPACE, Immunity (medical), International Space Station, Research, Key, United States national laboratories, Secrecy, Immune system, Patient, Conditional sentence, Bacteria, Scientific research on the International Space Station, Virus, ISS, Disease, Vaccine, Upward

But for the elderly and those facing chronic diseases, the immune system can wear down over time.

Key Points: 
  • But for the elderly and those facing chronic diseases, the immune system can wear down over time.
  • To better understand the relationship between immune aging and how the body heals itself, a team of scientists took their research to new heights by leveraging the International Space Station (ISS) National Laboratory to study microgravity's effects on immune cell function.
  • As people age, their immune system function declines gradually over time, which makes them increasingly vulnerable to infection and disease.
  • This makes the unique conditions of the space station an ideal platform for studying the immune aging process.

Abata Therapeutics to Present at Upcoming Investor and Industry Events in June

Retrieved on: 
Wednesday, May 31, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Immunity (medical), Regulatory T cell, Biology, Therapy, Innovation, Patient, Autoimmunity, Inflammation, Pharmaceutical industry

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer will present at the following events in June:

Key Points: 
  • Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer will present at the following events in June:
    World Medical Innovation Forum: Panel discussion titled “The Innovation Gap: Old Dog, New Tricks – Reprogramming the Immune System” on Wednesday, June 14, 2023, at 9:15 a.m.
  • ET in Boston, MA.

American Thoracic Society Selects Immune IQ to Present Breakthrough Point-of-Care Diagnostic Technology at the 2023 Respiratory Innovation Summit

Retrieved on: 
Wednesday, May 17, 2023
Infection, Survivor, Hospice and palliative medicine, Office of Inspector General, U.S. Department of Health and Human Services, Sepsis, Health, Human services, ATS, Immunity (medical), COVID-19, Cancer, Quality of life, Intelligence, Organ dysfunction, EST, Research, American Thoracic Society, Death, Immune system, Honeywell, Artificial intelligence, Diagnosis, Success, Anesthesiology, Disease, Johns Hopkins School of Medicine, Vaccine

Immune IQ founder and CEO, David Deetz, will present on May 20, 2023, at 11:30 am EST.

Key Points: 
  • Immune IQ founder and CEO, David Deetz, will present on May 20, 2023, at 11:30 am EST.
  • "It is an honor to have been chosen by the American Thoracic Society to present at this year's Respiratory Innovation Summit and share how Immune IQ is transforming the way we diagnose and treat a wide range of health conditions by harnessing the power of the human immune system."
  • The Immune Reveal point-of-care diagnostic platform provides diagnostic data more rapidly and cost-effectively than ever before.
  • Immune IQ is pursuing sepsis identification as the initial test to be commercialized on the Immune Reveal platform.

DaVita Recognizes Nephrology Nurses with DAISY Award

Retrieved on: 
Wednesday, May 10, 2023
WE, Idiopathic disease, Nursing, Respect, Immunity (medical), ITP, Somatosensory system, Healer, DAISY, Patient, IA Financial Group, DaVita Inc., Primary care behavioral health, Immune thrombocytopenic purpura, Kidney, Connection, Health, Immune system, Environment, Family, Memory, FAAN

DENVER, May 10, 2023 /PRNewswire/ -- DaVita Inc. today announced that 56 of its nephrology nurses were honored with the DAISY Award® for Extraordinary Nurses during National Nurses Week. The award is part of the DAISY Foundation's mission to recognize nurses who provide outstanding, compassionate care in more than 5,800 health care facilities across the country.

Key Points: 
  • today announced that 56 of its nephrology nurses were honored with the DAISY Award® for Extraordinary Nurses during National Nurses Week.
  • The award is part of the DAISY Foundation's mission to recognize nurses who provide outstanding, compassionate care in more than 5,800 health care facilities across the country.
  • "In Italian, DaVita means 'to give life,' which is exactly what our nurses do every day," said Tina Livaudais, chief nursing officer for DaVita.
  • The kind of work the nurses at DaVita are called on to do every day epitomizes the purpose of the DAISY Award."

Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis

Retrieved on: 
Sunday, November 13, 2022
Online, Trial of the century, Clinical trial, Rheumatoid arthritis, Lymph, Cancer, Security (finance), Degenerative disease, Division, Postherpetic neuralgia, RTX, Vaccine, Antibody, Autoimmune disease, American College, Phase, RA, Pain, PHN, Stanford University School of Medicine, Patient, FDA, Osteoarthritis, Immunity (medical), Therapy, Sciatica, Immunology, Immune system, Annual report, KOL, Skin, Injection, Risk, American College of Rheumatology, TRPV1, ACR, Lymphatic system, TNF, SAN, Mayflower, Pharmaceutical industry, Generic drug, Medicine, COVID-19, Rheumatology

The event will feature a deep dive and discussion of the clinical study design and clinical data demonstrating improved therapeutic outcomes and lymphatic functioning in rheumatoid arthritis (RA) patients receiving the Sofusa Lymphatic Drug Delivery System (Sofusa) treatment.

Key Points: 
  • The event will feature a deep dive and discussion of the clinical study design and clinical data demonstrating improved therapeutic outcomes and lymphatic functioning in rheumatoid arthritis (RA) patients receiving the Sofusa Lymphatic Drug Delivery System (Sofusa) treatment.
  • This data was accepted and presented today at the American College of Rheumatology (ACR) Convergence 2022 meeting in Philadelphia.
  • Chris Jeffers, Ph.D., J.D., Chief Executive Officer of Mayflower BioVentures and Hibiscus BioTechnology, will moderate this panel discussion following the ACR conference.
  • ZTlido is a registered trademark owned by Scilex Pharmaceuticals Inc. All other trademarks are the property of their respective owners.

Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Forward-looking statement, Doctor of Philosophy, U.S. Securities and Exchange Commission, OTC, Interim, TLR4, Board, Therapy, Goal, Company, Disease, Receptor (biochemistry), CEO, Security (finance), Acquisition, Management, Risk management, Immunity (medical)

In addition, Dr. Clifford Selsky resigned from his position as a Director of Immune on November 4, 2022.

Key Points: 
  • In addition, Dr. Clifford Selsky resigned from his position as a Director of Immune on November 4, 2022.
  • Kevin Phelps, a long-standing Immune Director stated, We wish Dr. Wilson and Dr. Selsky success in their endeavors and appreciate their efforts in support of Immune and its employees.
  • The Company believes that the management changes will not affect its ability to realize its strategic goals, including the development of the long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122.
  • Immune does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.